doc. MUDr. Alexandr Poprach, Ph.D.
docent – Klinika komplexní onkologické péče
Počet publikací: 144
2024
-
11C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET)
BMC Cancer, rok: 2024, ročník: 24, vydání: 1, DOI
-
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
New England Journal of Medicine, rok: 2024, ročník: 391, vydání: 8, DOI
-
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2<sup>EV</sup> Study
Targeted Oncology, rok: 2024, DOI
-
Long-Term Efficacy and Safety of Enzalutamide Monotherapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Report
CASE REPORTS IN ONCOLOGY, rok: 2024, ročník: 17, vydání: 1, DOI
-
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project
Targeted Oncology, rok: 2024, DOI
-
Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy
Targeted Oncology, rok: 2024, ročník: 19, vydání: 2, DOI
-
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)
Targeted Oncology, rok: 2024, DOI
-
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations
Cancer immunology, immunotherapy, rok: 2024, ročník: 73, vydání: 8, DOI
-
Transmembrane glycoprotein GPNMB is a candidate predictive biomarker and potentially a therapeutic target in metastatic renal cell carcinoma
Rok: 2024, druh: Konferenční abstrakty
2023
-
Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma
Targeted Oncology, rok: 2023, ročník: 18, vydání: November 2023, DOI